Expression of Cancer-Testis Genes in Brain Tumors

Myoung-Hee Lee, M.D.1
Eun-Ik Son, M.D.1
Ealmaan Kim, M.D.1
In-Soo Kim, M.D.1
Man-Bin Yim, M.D.1
Sang-Pyo Kim, M.D.2

Objective: Cancer-testis (CT) genes are considered promising candidates for immunotherapeutic approaches. The aim of this study was to investigate which CT genes should be targeted in immunotherapy for brain tumors.

Methods: We investigated the expression of 6 CT genes (MAGE-E1, SOX-6, SCP-1, SSX-2, SSX-4, and HOM-TES-85) using reverse-transcription polymerase chain reaction in 26 meningiomas and 32 other various brain tumor specimens, obtained from the patients during tumor surgery from 2000 to 2005.

Results: The most frequently expressed CT genes of meningiomas were MAGE-E1, which were found in 22/26 (85%) meningioma samples, followed by SOX-6 (9/26 or 35%). Glioblastomas were most frequently expressed SOX-6 (6/7 or 86%), MAGE-E1 (5/7 or 71%), followed by SSX-2 (2/7 or 29%) and SCP-1 (1/7 or 14%). However, 4 astrocytomas, 3 anaplastic astrocytomas, and 3 oligodendrogial tumors only expressed MAGE-E1 and SOX-6. Schwannomas also expressed SOX-6 (5/6 or 83%), MAGE-E1 (4/6 or 67%), and SCP-1 (2/6 or 33%).

Conclusion: The data presented here suggest that MAGE-E1 and SOX-6 genes are expressed in a high percentage of human central nervous system tumors, which implies the CT genes could be the potential targets of immunotherapy for human central nervous system tumors.

KEY WORDS: Cancer-testis gene, Brain tumor, MAGE-E1, SOX-6, SCP-1, SSX-2.

INTRODUCTION

Cancer-testis (CT) genes are potentially suitable targets for tumor vaccines of human cancers because of their high immunogenicity and their relatively restricted normal tissue distribution except for the testis. To date, forty-seven CT gene families, including 93 genes have been described. The CT genes have been demonstrated to induce spontaneous cellular and/or humoral immune responses. Most of CT genes are mainly located on the X-chromosome and being used as targets in several vaccination trials. Recently, the expression analysis of seven CT genes showed that 60% of astrocytomas expressed at least one CT genes. However, the expression of CT genes in the various human central nervous system tumors is little known. In this study, we analyzed the frequency for the expression of six CT genes in 26 meningiomas and 32 other various brain tumor specimens, using reverse-transcription polymerase chain reaction. In this study, we examined the expression of six CT genes (MAGE-E1, SOX-6, SCP-1, SSX-2, SSX-4, and HOM-TES-85) in 26 meningiomas and 32 other various brain tumors as a preliminary study as well as the possibility of the potential targets of immunotherapy.

MATERIALS AND METHODS

Samples

Twenty-six meningiomas and thirty-two various brain tumor samples were obtained from patients during surgery in our Medical Center from 2000 to 2005. Of the 32 various brain tumors, there were seven glioblastomas, four astrocytomas, three anaplastic astrocytomas, three oligodendrogial tumors, six schwannomas, two ependymomas, two primitive neuroectodermal tumors, two craniopharyngiomas, one ganglioglioma, one pituitary adenoma, and one hemangioblastoma. The human testis from autopsy used to positive control for CT genes.

Biopsy samples were snap-frozen within 1 hour after excision. The part of tumor was fixed in formalin and embedded in paraffin for conventional H&E-stained histologic...
sections. The other part of tumor was snap-frozen in liquid nitrogen and microscopically checked for the presence of neoplastic tissue and the amount of contaminating non-neoplastic tissue in cryostat sections before use for reverse-transcription polymerase chain reaction (RT-PCR). The use of RNA material derived from human subjects has been approved by the Institutional Review Board of our Medical Center. The diagnosis of brain tumors was confirmed in all cases by pathologist.

**Reverse transcription-polymerase chain reaction (RT-PCR)**

Total RNA was isolated from brain tumor samples by TRIzol (Life Technologies, Inc.). Five micrograms of total RNA was reverse transcribed to cDNA using M-MLV reverse transcriptase (Promega Corp., Madison, WI) according to the manufacturer's instructions with oligo (dT) primer. The RT reactions were performed at 42°C for 60 min. Single-stranded cDNA was amplified by PCR with primers for MAGE-E1, SOX-6, SCP-1, SSX-2, SSX-4, and HOM-TES-85, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The primers for the respective CT genes were as follows: MAGE-E1 sense, 5'-CCT GTG CTT TCT CTC AGG CT-3'; MAGE-E1 antisense, 5'-TCT CTC TCT CCT CGC TGC-3'; SOX-6 sense, 5'-GAT GCC ATC TCC ACA GC-3'; SOX-6 antisense, 5'-GCT GCA GAG CCA TTC ATT GC-3'; SCP-1 sense, 5'-GTA CAG CAA GCA AGC AAC TGA ATG-3'; SCP-1 antisense, 5'-GAA GGA ACT GCT TTA GAA TCC AAT ATT C-3'; SSX-2 sense, 5'-GTG CTG CTC AAA TAC CAG AGA AGA TC-3'; SSX-2 antisense, 5'-TTT TGG GTC CAG ATC TCT CGT G-3'; SSX-4 sense, 5'-AAA TCG TCT ATG TGT ATA TGA AGC T-3'; SSX-4 antisense, 5'-GGG TCG CTG ATC TCT TCA TAA-3'; HOM-TES-85 sense, 5'-GGA GAG GCT ACT CAA GAT GCA GAA GC-3'; HOM-TES-85 antisense, 5'-CTG AGT GAC TAT GAC ATC TCT AGT-3'; GAPDH sense, 5'-GTT GAA GGT CGT GGA CGG CG-3'; GAPDH antisense, 5'-GAT AGG AAC ACG GAA GGC CA-3'. The following PCR conditions were applied: MAGE-E1, SOX-6, and HOM-TES-85, 35 cycles of denaturation at 94°C for 30 s, annealing at 58°C for 30 s, and extension at 72°C for 30 s; SCP-1, 35 cycles of denaturation at 94°C for 30 s, annealing at 60°C for 30 s, and extension at 72°C for 30 s; SSX-2 and SSX-4, 35 cycles of denaturation at 94°C for 30 s, annealing at 63°C for 30 s, and extension at 72°C for 30 s; GAPDH, 18 cycles of denaturation at 94°C for 30 s, annealing at 57°C for 30 s, and extension at 72°C for 30 s. GAPDH was used as an internal control to evaluate relative expression of CT genes.

**RESULTS**

MAGE-E1 was expressed in 22 cases (85%) of 26 meningiomas and SOX-6 was positive in 9 cases (35%) of 26 meningiomas, and two fibrous meningiomas coexpressed SOX-6 with SSX-4 and MAGE-E1 with HOM-TES-85, respectively. In 7 glioblastomas, SOX-6 were most frequently expressed (86%, 6/7) and MAGE-E1 (71%, 5/7), followed by SSX-2 (29%, 2/7) and SCP-1 (14%, 1/7). However, four astrocytomas, three anaplastic astrocytomas and three oligodendrogial tumors expressed MAGE-E1 and SOX-6 without any other CT genes. Other tumors (ependymomas, PNETs and craniopharyngiomas) predominantly expressed SOX-6 and MAGE-E1 as well. Schwannomas also expressed SOX-6 (83%, 5/6), MAGE-E1 (67%, 4/6), and SCP-1 (33%, 2/6). One hemangioblastoma was negative for all CT genes tested. These results are shown in Table 1 and Fig. 1.

**DISCUSSION**

CT genes are expressed at different frequencies of a wide range of different types of malignancy, but not in normal tissues except testis, ovary and placenta. This fact makes CT genes especially attractive targets for specific tumor immunotherapy. Many kinds of CT genes, such as MAGE-3, GAGE/PAGE/XAGE, NY-ESO-1/LAGE-1, SSX-2, SPANX, TRAG-3, BAGE, OY-TES, CT17, NY-BR-3, SCP-1, and SOX-G have been reported. To date, forty-seven CT gene families, including

<table>
<thead>
<tr>
<th>Table 1. Expression of cancer-testis genes by human central nervous system tumors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor</td>
</tr>
<tr>
<td>------------------</td>
</tr>
<tr>
<td>Meningioma</td>
</tr>
<tr>
<td>Glioblastoma</td>
</tr>
<tr>
<td>Astrocytoma</td>
</tr>
<tr>
<td>Anaplastic As</td>
</tr>
<tr>
<td>Oligodendrogial tumor</td>
</tr>
<tr>
<td>Ependymoma</td>
</tr>
<tr>
<td>Craniopharyngioma</td>
</tr>
<tr>
<td>Gangliogioma</td>
</tr>
<tr>
<td>Schwannomas</td>
</tr>
<tr>
<td>Pituitary adenoma</td>
</tr>
<tr>
<td>Hemangioblastoma</td>
</tr>
</tbody>
</table>
CT genes were expressed in human brain tumors. An equal amount of testis RNA was used as a representative positive control. A: expression of SOX-6 by testis (T) markers, meningiomas (1, 2), glioblastomas (3, 4), astrocytoma (5), anaplastic astrocytoma (6), hemangioblastoma (7), oligodendrogliomas (8, 9), ependymoma (10), primitive neuroectodermal tumor (PNET) (11), cranialpharyngioma (12), ganglioglioma (13), schwannomas (14), and pituitary adenoma (15). B: expression of MAGE-E1 by testis (T) markers, composed of MAGE-E1a and/or -E1b (lower bands, 473 bp) and E1c (upper bands, 882 bp), meningiomas (1, 2), glioblastomas (3, 4), astrocytoma (5, 6), anaplastic astrocytoma (7), oligodendrogliomas (8, 9), ependymoma (10), hemangioblastoma (11), PNET (12), cranialpharyngioma (13), ganglioglioma (14), and schwannomas (15). C: expression of SCP-1 by testis (T) markers, meningiomas (1, 2), glioblastomas (3, 4), astrocytoma (5, 6), anaplastic astrocytoma (7), oligodendrogliomas (8, 9), ependymoma (10), meningiomas (11), PNET (12), cranialpharyngioma (13), ganglioglioma (14), and schwannomas (15). Our preliminary data may provide basic idea for expression of CT genes for meningiomas.

93 genes have been recently described. Immunotherapy for brain tumors is one of the alternative approaches that have been rarely studied in detail in the various brain tumors. To evaluate CT genes for diagnostic and therapeutic approach, accurate information on the CT genes expression pattern in various brain tumors is essential. Among the many CT genes, SOX-6 may be a useful marker for the diagnosis of neuronal and glial brain tumors. Sasaki et al. reported that MAGE-E1 expression was detected only in brain and MAGE-E1 were specifically expressed in glioma cells among cancer cells. Some of many CT genes were expressed in human brain tumors. Therefore, we examined MAGE-E1, SOX-6, SCP-1, SSX-2, SSX-4, and HOM-TES-85 expression using RT-PCR in various brain tumor tissues and normal testis tissue as positive control.

Our results show a high expression rate of MAGE-E1 and SOX-6 gene mRNA in meningioma tissues and various brain tumors. In meningioma cases, two fibrous meningiomas coexpressed SOX-6 with SSX-4 and MAGE-E1 with HOM-TES-85, respectively. Sahin et al. reported that meningiomas express only SCP-1. From the data of present study, no apparent expression of SCP-1 was detected in meningiomas. Interestingly, we demonstrate that MAGE-E1 and SOX-6 are commonly expressed in meningiomas. Although the most effective treatment of meningiomas is surgery, adjuvant immunotherapy or chemotherapy could be considered in cases of unresectable or failed radiotherapy. Our preliminary data may provide basic idea for expression of CT genes for meningiomas.

Importantly, the most relevant findings of this study are a high incidence of expression of the MAGE-E1 and SOX-6. MAGE-E1 and SOX-6 in low or high grade glioma and other various benign brain tumors. However, our study only provided qualitative analysis for expression of CT genes and no quantitative results were obtained. Expression of MAGE-E1 and SOX-6 was never detected in normal tissue samples. Previously, MAGE-E1 and SOX-6 were reported glioma-specific CT genes of brain tumors. In the present study, MAGE-E1 and SOX-6 genes may serve as an attractive target for immunotherapy designed for especially high grade brain tumor.

CONCLUSION

MAGE-E1 and SOX-6 may make ideal candidate genes for antigen-specific tumor immunotherapy and could become an adjuvant diagnostic tool for brain tumors. Further related studies, such as quantitative RT-PCR, immunohistochemistry, histological grade and clinical outcome with sufficient cases may be necessary.

Acknowledgement

This work was supported by the research promoting grant from the Institute for Medical Genetics, Keimyung University.

References

7. Goodyear O, Piper K, Khan N, Starczynski J, Mahendra P, Pratt G, et al: CD8+ T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency...
correlates with disease burden. *Blood* **106**:4217-4224, 2005